DATROWAY Powder for concentrate for solution for infusion Ref.[115207] Active ingredients: Datopotamab deruxtecan

Source: European Medicines Agency (EU)  Revision Year: 2025  Publisher: Daiichi Sankyo Europe GmbH, Zielstattstrasse 48, 81379 Munich, Germany

Product name and form

Datroway 100 mg powder for concentrate for solution for infusion.

Pharmaceutical Form

Powder for concentrate for solution for infusion.

White to yellowish white lyophilised powder, which has a cake-like appearance.

Qualitative and quantitative composition

One vial of powder for concentrate for solution for infusion contains 100 mg of datopotamab deruxtecan. After reconstitution, one vial of 5 mL solution contains 20 mg/mL of datopotamab deruxtecan (see section 6.6).

Datopotamab deruxtecan is an antibody-drug conjugate (ADC) that contains a humanised anti-TROP2 IgG1 monoclonal antibody (mAb) produced by mammalian (Chinese Hamster Ovary) cells, covalently linked to DXd, an exatecan derivative and a topoisomerase I inhibitor, via a tetrapeptide-based cleavable linker. Approximately 4 molecules of deruxtecan are attached to each antibody molecule.

Excipient with known effect: Each 100 mg vial contains 1.50 mg of polysorbate 80 (E433).

For the full list of excipients, see section 6.1.

Active Ingredient

Datopotamab deruxtecan is a TROP2-directed antibody-drug conjugate. The antibody is a humanised anti-TROP2 IgG1 attached to deruxtecan, a topoisomerase I inhibitor (DXd) bound by a tetrapeptide-based cleavable linker. The antibody-drug conjugate is stable in plasma. The antibody binds to TROP2 expressed on the surface of certain tumour cells. After binding, datopotamab deruxtecan undergoes internalisation into the tumour cells. Subsequently, the release of DXd results in DNA damage and apoptotic cell death via topoisomerase I inhibition.

List of Excipients

L-histidine
L-histidine hydrochloride monohydrate
Sucrose
Polysorbate 80 (E433)

Pack sizes and marketing

Datroway is provided in a 10 mL Type 1 amber borosilicate glass vial sealed with a fluoro-resin laminated butyl rubber stopper, and a polypropylene/aluminium blue flip-off crimp cap.

Each carton contains 1 vial.

Marketing authorization holder

Daiichi Sankyo Europe GmbH, Zielstattstrasse 48, 81379 Munich, Germany

Marketing authorization dates and numbers

EU/1/25/1915/001

Drugs

Drug Countries
DATROWAY Austria, Estonia, Italy, Lithuania, United States

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.